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Inhibitory neurotransmission plays an important role in controlling excitability within 
nociceptive circuits of the spinal cord dorsal horn. Loss of inhibitory signalling is thought to 
contribute to the development of pathological pain. Preclinical studies suggest that increasing 
inhibitory glycinergic signalling is a good therapeutic strategy for treating pain. One approach 
to increase synaptic glycine is to inhibit the activity of the glycine transporter 2 (GlyT2) on 
inhibitory nerve terminals. These transporters are involved in regulating glycine 
concentrations and recycling glycine into presynaptic terminals. Inhibiting activity of GlyT2 
increases synaptic glycine, which decreases excitability in nociceptive circuits and provides 
analgesia in neuropathic and inflammatory pain models. 
Experimental Approach: 
We investigated the effects of reversible and irreversible GlyT2 inhibitors on inhibitory and 
excitatory neurotransmission in the dorsal horn. The effect of these drugs on synaptic 
signalling was determined using patch-clamp electrophysiology techniques to measure 
glycine- and NMDA- mediated postsynaptic currents in spinal cord slices in vitro. 
Results: 
We compared activity of four compounds that increase glycinergic tone with a corresponding 
increase in evoked glycinergic postsynaptic currents. We found these compounds do not 
deplete synaptic glycine release over time. Interestingly, we found that none of these 
compounds increased glycine-mediated excitatory signalling through NMDA receptors. 
Results suggests that these compounds preferentially inhibit GlyT2 over the glycine 
transporter 1 (GlyT1) with no potentiation of the glycine receptor or spill-over from inhibitory 
to excitatory synapses.  
Conclusions:  
GlyT2 inhibitors increase inhibitory neurotransmission in the dorsal horn and have potential 






ALX1393, O-[(2-Benzyloxyphenyl-3-flurophenyl)methyl]-L-serine; AP5, (2R)-amino-5-
phosphonovaleric acid; CNQX, 6-Cyano-7-nitroquinoxaline-2,3-dione; Dichlorokynurenic 
acid, DCKA; GAT1, GABA transporter 1; GlyT1, Glycine transporter 1;  GlyT2, glycine 
transporter 2; IPSC, inhibitory postsynaptic current; NAGly,  N-arachydonoyl-glycine; 
NOGly, N-[3-([1,1-Biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methylglycine, NFPS;  
N-Oleoylglycine; OL-Carn, Oleoyl-L-carnitine; ORG25543, N-[[1-
(Dimethylamino)cyclopentyl]methyl]-3,5-dimethoxy-4-(phenylmethoxy)benzamide 
hydrochloride; SLCC6, sodium-dependent solute carrier family 6 transporters; QX-314.Cl, N-
(2,6 Dimethylphenylcarbamoylmethyl) triethylammonium chloride. 
 
Introduction:  
Regulation of sensory processing in the spinal cord is mediated through the fast inhibitory 
neurotransmitters glycine and γ-aminobutyric acid (GABA) (Zeilhofer et al., 2012).  These 
inhibitory neurotransmitters play important roles in limiting excitability in the nociceptive 
circuit of the dorsal horn and when the receptors of these neurotransmitters are antagonized in 
vivo, this leads to the symptoms of pathological pain (Yaksh 1989). Studies from our group 
and others using animal models of neuropathic pain have shown that loss of inhibitory 
GABAergic and glycinergic neurotransmission, or disinhibition, occurs in the dorsal horn in 
peripheral nerve-injury (Yaksh 1989; Sherman, and Loomis 1995, 1996; Sivilotti, and Woolf 
1994; Imlach et al., 2016). The crucial role of glycine signalling in the control of nociceptive 
transmission in the dorsal horn was recently demonstrated in studies where glycinergic neurons 
were either ablated or activated in mice, which caused pain and analgesia, respectively (Foster 
et al., 2015). Since glycinergic neurotransmission has such a profound influence on whether or 
not nociceptive signals are transmitted  to the brain, this system is an attractive target for pain 
therapeutic development (Imlach 2017). 
Glycine concentrations at both inhibitory and excitatory synapses in the CNS are regulated by 
the glycine transporters 1 and 2 (GlyT1 and GlyT2) which are part of the sodium-dependent 
solute carrier family 6 (SLCC6) transporters. GlyT1 is expressed by astrocytes at inhibitory 
and excitatory synapses, while GlyT2 expression is restricted to inhibitory glycinergic neurons 
at presynaptic terminals (Zeilhofer et al., 2005). GlyT2 plays important roles regulating 
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synaptic glycine concentrations and recycling glycine back to the presynaptic terminals to 
maintain sufficient stores of glycine-containing vesicles (Zafra et al., 1995).  Many of the 
inhibitory interneurons that regulate nociceptive signalling in the dorsal horn are located in 
lamina III, an area where GlyT2 is highly expressed (Zeilhofer et al., 2012). GlyT2 more 
effectively reduces glycine concentration compared to GlyT1 and is able to reduce synaptic 
glycine to the low nanomolar range, preventing low level glycine receptor activation 
(Supplisson, and Roux 2002). This fine control of synaptic glycine levels by GlyT2, suggests 
that inhibiting the function of this transporter would reduce clearance of synaptic glycine and 
increase basal inhibitory neurotransmission, which in turn would reduce nociceptive signalling 
in the dorsal horn. However, the balance between complete and partial inhibition of GlyT2 is 
also an important factor, as too much inhibition reduces synaptic vesicle loading, thus 
preventing synaptic glycine release (Vandenberg et al., 2014). The effect of complete inhibition 
has been observed in GlyT2 knockout mice that suffer from severe motor deficiencies by the 
second postnatal week due to loss of glycine at the neuromuscular junction (Gomeza et al., 
2003). Conversely, partial knockdown of the GlyT2 gene using siRNAs results in a normal 
motor phenotype and the reduction in GlyT2 activity corresponds with reduced allodynia 
scores in a mouse model of neuropathic pain (Morita et al., 2008), suggesting that partial 
inhibitors of GlyT2 may avoid side effects caused by loss of synaptic glycine.  
Investigations of the therapeutic potential of the early GlyT2 inhibitors, ALX1393 and 
ORG25543, show they are analgesic when administered intravenously in the mouse 
neuropathic pain model (Morita et al., 2008).  However, ALX1393 also inhibits GlyT1 at 
higher concentrations, which may exacerbate pain symptoms by increasing glycine at 
excitatory NMDA receptors and increasing spinal sensitization (Mingorance-Le Meur et al., 
2013). The GlyT2 inhibitor ORG25543 has similar antinociceptive effects to ALX1393 in in 
vivo pain models and has been found to increase glycinergic tonic currents and evoked 
inhibitory post-synaptic current (eIPSC) decay time in spinal cord slices (Bradaia et al., 2004). 
However, ORG25543 is an irreversible inhibitor of GlyT2 and following an initial increase in 
glycinergic activity it causes a significant reduction in glycinergic eIPSCs in vitro suggesting 
that presynaptic glycine vesicle recycling is reduced to a level that does not support synaptic 
signalling (Gomeza et al., 2003). In a study by Wiles et al. (Wiles et al., 2006), the 
endocannabinoid N-arachydonoyl-glycine (NAGly) was shown to selectively and reversibly 
inhibit GlyT2 over GlyT1 and GAT1. NaGly has also been shown to act as an allosteric 
modulator of glycine receptors, with potentiation of 1 GlyR and inhibition of 2 and 3 
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(Yévenes and Zeilhofer, 2011). NAGly is found in high concentrations in the spinal cord and 
reduces pain in inflammatory and neuropathic models of pain through a mechanism that is 
independent of cannabinoid receptor activation (Succar et al., 2007; Vuong et al., 2008).  
Recently a number of lipid inhibitors including Oleoyl-L-carnitine (OL-Carn; C18 cis ω9  L-
Carnitine) and N-Oleoylglycine (NOGly; C18 cis ω9 glycine), that are based on the 
endogenous GlyT2 inhibitor NAGly, have been tested as GlyT2 inhibitors (Carland et al., 
2013). OL-Carn and NOGly have significantly different head groups but both have a C18 
(oleoyl) tail (Table 1). This difference in head group results in greater potency of OL-Carn at 
inhibiting GlyT2 expressed in oocytes but less reversibility compared to NAGly (Carland et 
al., 2013). Lipid compounds with variations in the tail length have also been investigated as 
GlyT2 inhibitors in oocyte studies and C18 has been found to have the highest affinity. Double 
bonds in the lipid tail also have an influence on efficacy with C18:0 and C18:2 derivatives 
showing less efficacy than the C18:1 derivative. In this study we compare the effects of OL-
Carn and NOGly with structurally related compounds, to investigate how differences in head 
and tail groups affect synaptic signalling in the spinal cord. Other compounds used in this study 
include compounds with different placements of the double bond (C18 cis ω8 glycine) and with 
shortened tail length (C16 cis ω3 glycine) (Table 1). These compounds may provide more 
specific and reversible inhibition of GlyT2 and may lead to more effective therapeutics for 
targeting glycine transport to treat pathological pain. 
Methods: 
Animals: Sprague-Dawley rats were housed in groups of 2-4, in individually ventilated cages 
with access to standard rat chow and 12 hour light-dark cycles. All animal experiments were 
performed in accordance with the University of Sydney animal ethics committee guidelines 
and were approved by the committee, University of Sydney Animal ethics approval number: 
2015/803. The animals used in this study were the same age, weight and gender. Animals were 
sourced from the Animal Resources Centre, Western Australia. Animal numbers were reduced 
as much as possible without compromising the amount of data points.  
 
Preparation of spinal cord slices. Adult male Sprague-Dawley rats (6-8 weeks at the time of 
slice preparation, ~180-260 g) (n = 29 rats) were anaesthetized with isoflurane, decapitated and 
the lumbar region of the spinal cord was removed. Parasagittal slices (340 μm thick) of spinal 
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cord were cut on a vibratome (Leica VT 1200s) in oxygenated ice-cold sucrose-based artificial 
CSF (sACSF) that contained (mM): 100 sucrose, 63 NaCl, 2.5 KCl, 1.2 NaH2PO4, 1.2 MgCl2, 
25 glucose, and 25 NaHCO3. Slices were transferred to a submerged chamber containing 
NMDG-based recovery ACSF (rACSF) for 15 minutes at 34°C, equilibrated with 95% O2 and 
5% CO2 and composed of (mM): 93 NMDG, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 
25 Glucose, 5 Na ascorbate, 2 thiourea, 3 Na pyruvate, 10 MgSO4 and 0.5 CaCl2, and adjusted 
to pH 7.4 with HCl. Following the recovery incubation, slices were transferred to normal 
oxygenated ACSF where they were allowed to recover for 1 hour at 34° C and then maintained 
at room temperature prior to transfer to the recording chamber. Normal ACSF had the 
following composition (mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 1.2 MgCl2, 2.5 CaCl2, 25 
glucose, and 11 NaHCO3 and was equilibrated with 95% O2 and 5% CO2.  
 
Electrophysiology. Slices were transferred to a recording chamber and superfused 
continuously at 2 ml/min with normal ACSF that had been equilibrated with 95% O2 and 5% 
CO2 and maintained at 34°C with an inline heater and monitored by a thermister in the slice 
chamber. Dodt-contrast optics was used to identify lamina II neurons in the translucent 
substantia gelatinosa layer of the superficial dorsal horn. A Cs+-based internal solution, which 
should minimise postsynaptic effects, was used to record electrically evoked inhibitory 
glycinergic post-synaptic currents (eIPSCs) or excitatory NMDA postsynaptic currents 
(eEPSCs) and contained (mM): 140 CsCl, 10 EGTA, 5 HEPES, 2 CaCl2, 2 MgATP, 0.3 
NaGTP, 5 QX-314.Cl, 2 (osmolarity 285-295 mosmol l-1). QX-314 was used in patch 
electrodes to prevent action potential firing when recording NMDA-receptor mediated 
currents, as action potential activity can prevent detection of synaptic currents, particularly at 
the depolarized potentials required for NMDAR currents. We did not observe loss of NMDAR-
mediated currents with QX-314. Patch electrodes had resistances between 3 and 5 M. 
Synaptic currents were measured in whole-cell voltage-clamp (-70 mV for eIPSCs or -40 mV 
for eEPSCs, not corrected for a liquid junction potential of 4 mV) from lamina II cells. Bipolar 
tungsten electrodes placed in the inner laminae (lamina III region) were used to elicit eIPSCs 
using a stimulus strength sufficient to evoke reliable eIPSCs. Neurons ventral to lamina II, in 
regions that are known to contain glycinergic neurons were stimulated in this study. 
Glycinergic IPSCs could not be elicited when from more superficial sites or when the 
stimulating electrode was moved to more ventral regions of the dorsal horn (deeper in lamina 
IV-V). Electrodes were placed in the dorsal root entry zone to stimulate eEPSCs. All eIPSCs 
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were recorded in CNQX (10 μM), AP5 (100 μM) and picrotoxin (80 μM). All eEPSCs were 
recorded in CNQX (10 μM), picrotoxin (80 μM) and strychnine (0.5 μM). IPSC and EPSC 
decay constants were determined using the fit exponential tool in Axograph X to fit the current 
from an average of 10 consecutive IPSCs for each condition. For eIPSCs, a mono-exponential 
function was fitted using a Simplex algorithm. For eEPSCs, the decay course was fitted to a 
double exponential function: f(t) = A1e(-t/1) + A2e(-t/2) where t is time, A1/A2 are peak 
amplitudes of the fast/slow decay components at t = 0 and 1/2 are the fast/slow decay time 
constants respectively. From this we calculated the weighted decay time constant (w) defined 
by: w = (A11)/(A1+A2) + (A22)/(A1+A2).  A mono-exponential function was fitted using 
a Simplex algorithm. Drugs were superfused onto slices at a rate of 2ml/min in normal 
oxygenated ACSF at 34°C and continued until a stable response was achieved which was 
followed by 10 consecutive measurements that were averaged for each data point. Vehicle 
(DMSO) controls were done for each concentration. At the conclusion of each experiment 
strychnine (0.5 μM) or AP5 (100 μM) were added to the superfusion solution to confirm that 
recorded currents were glycine- mediated IPSCs or NMDA-mediated EPSCs, respectively. 
Charge transfer of eIPSCs were determined by measuring the amplitude area using the 
AxoGraph measure function. The tonic current value (taken just before each eIPSC) was 
subtracted prior to calculating charge transfer to isolate the eIPSC charge without the tonic 
current component. 
 
Data analysis.  Both tonic current and eIPSC amplitudes were measured from 0 pA. Drug 
effects were normalized and expressed as % of baseline and presented as mean ± SEM. Data 
were analysed using Prism 6 (Version 6.03). Statistics were performed on data before it was 
normalized and normal distributions were confirmed using Prism software. Data is normalized 
in histograms because the amplitude of evoked currents vary significantly in between 
recordings. Comparisons of two treatments in the same group were made using a two-tailed 
paired t test. When multiple comparisons were tested, ANOVA with Sidaks or Fishers LSD 
post hoc test to correct for multiple comparisons were used, unless otherwise stated in figure 
legends. Significance threshold was set at * P < 0.05. Group sizes were a minimum of 5 
independent values, which is a number determined from previous studies. Data sets were 




Materials. Picrotoxin, CNQX, NFPS, ORG25543 and strychnine were purchased from Sigma 
Australia. QX-314 was purchased from Alomone Labs, Israel. AP5 was purchased from Tocris 
Bioscience, UK. All other chemicals were purchased from Sigma, Australia unless otherwise 
stated in the text. C18 cis ω8 Glycine and C16 cis ω3 glycine were synthesised at the Faculty 
of Science, the University of Technology Sydney. The structural identity and purity of 
synthesised compounds was determined by 1H and 13C NMR, HRMS, and elemental analysis. 
Stocks of lipids were made in DMSO.  
Nomenclature of targets and ligands. Key protein targets and ligands in this article are 
hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common 
portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), 
and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16. 
 
Results: 
Lipid GlyT2 inhibitors increase synaptic glycinergic tone of lamina II interneurons. 
Basal glycinergic tonic currents and electrically stimulated IPSCs were recorded from lamina 
II interneurons in whole-cell patch voltage clamp configuration in parasagittal spinal cord 
slices. Stimulating electrodes were placed in lamina III and the glycinergic component of the 
current was recorded in the presence of glutamatergic and GABAergic inhibitors CNQX (10 
M), AP5 (100 M) and Picrotoxin (80 M). Tonic current was calculated as the difference 
between baseline current before and after superfusion of the glycine receptor antagonist 
strychnine (0.5 M), which was applied at the conclusion of the experiment (Fig 1).  We 
investigated the effect of lipid inhibitors (0.1-100 M) on glycinergic tonic current and found 
significant increases with all inhibitors except C18 cis ω8 Glycine, at concentrations equal or 
greater than 1 M (Fig 1). The effects were dose-dependent with NOGly. The increase in eIPSC 
amplitude followed a similar pattern to the increase in basal tonic current and the two values 
were not significantly different, which suggests that these inhibitors have no effect on evoked 
release, but increase activity and therefore amplitude by increasing synaptic glycine levels. The 
compound that gave the largest significant increase in tonic and evoked currents was NOGly 
with 35.86 ± 10.2% and 30.7 ± 9.7% increase, respectively. Vehicle (DMSO) controls showed 
no significant differences in tonic or evoked IPSC amplitudes when compared to baseline (n = 
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5). Mean baseline eIPSC amplitudes for OL-Carn experiments were 246 ± 30 pA, NOGly were 
258 ± 54 pA, C16 cis ω3 glycine were 191 ± 25 pA and C18 cis ω8 were 238 ± 32 pA.  
We have previously found that these compounds have no detectable effect on GlyT1 expressed 
in oocytes (Mostyn et al, 2017, Table 1). To rule out any alternative modes of action, including 
activity at the glycine receptor, we performed occlusion experiments in lamina II neurons 
where slices were incubated with the GlyT2 inhibitor ORG25543 prior and during application 
of NOGly (Fig 2). There was no significant difference in tonic or evoked current amplitude in 
the presence ORG25543 and ORG25543 with NOGly. ORG25543 increased tonic current 
amplitude by 36.4 ± 18.1% and NOGly in the presence of ORG25543 resulted in a tonic current 
of 49.1 ± 30.1%  over baseline (P = 0.59, n = 5). ORG25543 increased evoked current 
amplitude by 24.5 ± 4.5% and NOGly in the presence of ORG25543 resulted in an evoked 
current amplitude over baseline of 22.4 ± 7.5% (P = 0.62, n=5). 
Effect of lipid GlyT2 inhibitors on decay time and charge transfer of evoked glycinergic 
IPSCs. 
It has been previously shown that the GlyT2 inhibitors NAGly and ALX-1393 increase the 
decay time of electrically evoked glycinergic IPSCs due to increased synaptic glycine (Jeong 
et al., 2010). To determine whether the GlyT2 inhibitors used in this study prolong the 
glycinergic eIPSC decay in lamina II neurons, we fitted exponentials to the decay phase of the 
current traces of experiments shown in figure 1. In contrast to previously reported data for 
NAGly and ALX-1393, we found that in most cases there was no change in decay time, with 
the exception of 10 M C16 cis ω3 glycine which caused a 28.3 ± 6.7% increase compared to 
pre-drug decay time (Fig 3). To further investigate this lack of effect on decay time constant, 
we assessed the effects of 10 M NOGly on spontaneous mIPSC activity (Fig 4). We observed 
no change in either amplitude or decay in the presence of NOGly (P = 0.8 and 0.3 respectively, 
n = 7). 
Charge transfer was calculated on all eIPSCs with tonic current subtracted. This allowed us to 
investigate the charge transfer of the eIPSC independent of the tonic current component.  No 
changes were seen with any inhibitors at 0.1 M, but data showed increases in charge transfer 
with OL-Carn and C16 cis ω3 glycine at higher concentrations. As a percentage of baseline, 
OL-Carn increased charge transfer with values of 123 ± 7%, 123 ± 3% and 124 ± 8% for 1, 10 
and 100 M respectively (P = 0.04, 0.02 and 0.04, paired t-tests on raw data). NOGly gave no 
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significant change in charge compared to baseline with mean values of 94 ± 17%, 111 ± 20% 
and 102 ± 10% for 1, 10 and 100 M respectively. C16 cis ω3 glycine gave mean values of 
charge transfer compared to baseline of 106 ± 19%, 138 ± 25% and 133 ± 23% (P = 0.09. 0.04, 
0.4, paired t-tests on raw data) for 1, 10 and 100 M respectively. C18 cis ω8 glycine did not 
change the average charge transfer significantly with mean values compared to baseline of 97 
± 5, 109 ± 13 and 105 ± 9 for 1, 10 and 100 M respectively.  
 
NOGly does not deplete glycine from presynaptic vesicles following prolonged exposure. 
Irreversible inhibitors of GlyT2 such as ORG25543 have been shown to decrease presynaptic 
glycine vesicle recycling to a level that does not support synaptic signalling (Gomeza et al., 
2003). The compounds used in this study are partial inhibitors, so they are more likely to allow 
sufficient reuptake which would support glycinergic inhibition in the presence of the drug. To 
investigate vesicle depletion after prolonged exposure to NOGly, we compared mIPSC 
amplitude and decay before NOGly application and after 20 minute and 2 hours exposure to 
10 M NOGly. Mean amplitude before drug exposure was 28.2 ± 4.0 pA, which was not 
significantly different to the amplitude at 10 minutes, 27.1 ± 3.6 pA (P = 0.8, n = 6) or 2 hours, 
29.3 ± 1.0 pA (P = 0.8, n = 6). There was also no significant difference in delay time constant, 
which was 4.1 ± 0.4 ms before drug exposure, 3.4 ± 0.3 ms after 10 minutes (P = 0.3, n = 6) 
and 4.5 ± 0.5 ms after 2 hours (P = 0.5, n =6) (Fig 4). 
 
Excitatory NMDA-mediated currents are not affected by the lipid inhibitors.  
At excitatory synapses, glycine acts as a co-activator for NMDA receptor mediated synaptic 
transmission. During periods of high presynaptic activity in the dorsal horn, glycine released 
from inhibitory interneurons can escape the synaptic cleft and activate NMDA receptors in the 
area, which is referred to as spill-over (Ahmadi et al., 2003).  Increasing synaptic glycine by 
inhibition of GlyT2 at inhibitory synapses may increase the chance of enhanced NMDA 
activity at excitatory synapses if the spill-over is sufficient, which is undesirable as it would 
have a proalgesic effect. Inhibition of GlyT1 has previously been shown to increase the 
amplitude of evoked NMDA-mediated EPSCs through the activity of this transporter at 
excitatory synapses (Raiteri, and Raiteri 2010).  In this study, lipid inhibitors were applied in 
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the presence of the CNQX (10 M),  picrotoxin (80 μM) and strychnine (0.5 μM) to block 
AMPA-, GABA- and glycine-mediated synaptic currents and EPSCs were elicited by dorsal 
rootlet stimulation while holding lamina II neurons at -40 mV to prevent voltage-dependent 
block by endogenous Mg2+.  We have previously published data to show that picrotoxin has 
the same activity as bicuculline on inhibitory currents in spinal cord slices in the concentrations 
used (Imlach et al., 2016). None of the GlyT2 inhibitors used in this study increase the 
amplitude or decay time constant of NMDA-mediated eEPSCs (Fig 5).  
Previous studies have demonstrated that CNQX (10 uM) does not inhibit potentiation of 
NMDA-mediated eEPSCs by exogenously applied glycine in spinal cord slices (Bradaia et al., 
2004). To confirm the lack of antagonistic activity of CNQX at the glycine binding site of 
NMDA receptors in our experiments, we performed control experiments under the same 
conditions with dichlorokynurenic acid (DCKA), an antagonist of the glycine site of the 
NMDA receptor. We found that 1 M DCKA reduced NMDA-mediated eEPSCs by 42.7 ± 
3.0% in the presence of 10 M CNQX (n = 5). 
To strengthen these findings, we also performed control experiments using the GlyT1 inhibitor, 
NFPS. Studies by other groups have shown that this inhibitor increases amplitude of NMDA-
mediated synaptic currents (Jeong et al., 2010). Our results showed mean time constants were 
140 ± 26 ms at baseline and 176 ± 43 ms in the presence of NFPS (P = 0.12, n = 5). NMDA 
current amplitude increased from 57 ± 6 pA at baseline to 65 ± 7 pA with NFPS (P = 0.03, n = 
5). 
Discussion and Conclusions. 
The aim of this study was to investigate the effect of lipid inhibitors of GlyT2 on synaptic 
transmission at inhibitory and excitatory synapses within the dorsal horn. Oocyte studies show 
similar GlyT2 IC50 values for the four compounds tested, which range from 0.32 to 0.81 M 
(Mostyn et al., 2017; Carland et al., 2013; Wiles et al., 2006). In the dorsal horn all compounds 
also had similar effects on glycinergic transmission, which is likely to be due to the small 
differences in GlyT2 IC50. We show that the lipids with glycine head groups retain the effects 
on inhibitory transmission of the less reversible than OL-Carn, which has a carnitine head 
group. NOGly which has the same tail as OL-Carn gave maximal increases of 35.86 ± 10.2% 
and 30.7 ± 9.7% for tonic and eIPSC amplitudes, while OL-Carn increased tonic current by 




Another measure of increased synaptic glycine is an increased decay time constant of eIPSCs. 
It has previously been shown that ORG25543 increases both glycinergic tonic currents and the 
decay time eIPSCs in spinal cord slices (Bradaia et al., 2004). In the current study we found 
that only one of these compounds, C16 cis ω3 glycine, caused a significant increase in decay 
time, which only occurred at 10 M. Since the size of the eIPSCs response can mask more 
subtle effects on decay, we also compared the time constants of spontaneous mIPSC events 
following an incubation in NOGly. This data showed no difference in mIPSC kinetics or 
amplitude, which supports the results we obtained when analysing eIPSC events. Interestingly, 
the increased delay we observed in C16 cis ω3 glycine eIPSCs was also reflected in the eIPSC 
charge transfer in response to 10 M C16 cis ω3 glycine, which was significantly increased. 
OL-Carn also produced significant increases in eIPSC charge transfer at concentrations 
between 1-100 M, which may be due to its longer lasting activity since it is a less reversible 
compound. The general lack of effect on both eIPSC decay and charge transfer would suggest 
that these glycine head group partial inhibitors are much less effective on GlyT2 than 
previously described inhibitors of GlyT2 and GlyT1.  
To rule out any alternative modes of action, including activity at the glycine receptor and 
GlyT1, we performed an occlusion experiment where slices were incubated with ORG25543 
prior and during application of NOGly. These results showed no additional increase in 
glycinergic transmission with NOGly, which suggests there is no potentiation of the glycine 
receptor. This differs to the structurally similar compound NAGly which has also been shown 
to act as an allosteric modulator of glycine receptors, with potentiation of 1 GlyR and 
inhibition of 2 and 3 (Yévenes and Zeilhofer, 2011).  
 
It has been previously shown that irreversible inhibitors of GlyT2 such as ORG25543 can 
decrease glycinergic signalling due to reduced vesicle recycling. Following an initial increase 
in glycinergic activity these compounds cause a reduction in glycinergic eIPSCs in vitro 
suggesting that the presynaptic glycine vesicle recycling is reduced to a level that does not 
support synaptic signalling (Gomeza et al., 2003). To test the effect of lipid GlyT2 inhibitors 
on rundown, we measure mIPSC amplitude and decay over a two hour incubation in NOGly. 
We found no change in either amplitude or decay, which suggests that NOGly does not reduce 
vesicle recycling.  
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To investigate whether these lipid inhibitors increased glycine-mediated excitatory activity in 
the dorsal horn, we measured their effect on NMDA-mediated currents. For these experiments 
we used one concentration of drug (10 M) that we found to be effective at increasing 
glycinergic tone in the first set of experiments. At excitatory synapses, glycine acts as a co-
activator for NMDA receptor mediated synaptic transmission. Increased glycine at these 
synapses may result from decreased GlyT2 activity and spill-over to excitatory synapses, or 
decreased activity of GlyT1 which is involved in glycine transport at excitatory synapses. In 
this study we found that none of the lipid inhibitors increased eEPSC amplitude or decay of 
NMDA-mediated eEPSCs. This suggests that there is no spill-over of glycine from inhibitory 
synapses and these compounds have no effect on GlyT1. These are desirable properties, since 
NMDA activation is likely to exacerbate pain symptoms by increasing excitation and spinal 
sensitization (Mingorance-Le Meur et al., 2013). 
Modifications in tail length and double bond position with the glycine head group drugs had 
no significant difference in activity across concentrations. Although these structural changes 
have the potential to cause subtle differences in activity, none of these modifications abolish 
or greatly increase activity. This would suggest these compounds may have similar potencies 
in vivo, but this is yet to be tested in animal pain models.  
 
In conclusion, we show that lipid inhibitors of GlyT2 are effective at increasing glycinergic 
neurotransmission in the dorsal horn and neurotransmission is increased by all compounds 
with specific activity at inhibitory synapses and not at excitatory synapses. (Fig 6). There is a 
great need for new therapeutics to treat chronic pain conditions and targeting glycinergic 
signalling in the spinal cord is a promising strategy. In neuropathic and inflammatory pain 
conditions, glycinergic signalling is greatly reduced and increasing signalling through glycine 
receptors in the dorsal horn has antinociceptive effects.  Due to relatively localised expression 
of GlyT2 in the spinal cord, these drugs are likely to have good side effect profiles. Therefore, 
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Table 1. Structures and GlyT inhibitor properties of compounds used in this study. IC50 data 
shows inhibition of 30 µM glycine transport by GlyT2 and GlyT1, expressed in Xenopus 
laevis oocytes from a) Mostyn et al, 2017 and b) Carland et al., 2013.  Data presented are 





Figure 1. GlyT2 inhibitors increase the amplitude of glycinergic currents in dorsal horn neurons. 
The effect of GlyT2 inhibitors (0.1-100 M) on the amplitude of glycinergic tonic and evoked IPSCs 
were recorded in lamina II neurons. A) Glycinergic currents are normalized to baseline and shown as a 
percentage. Examples of glycine-mediated eIPSC traces are shown for baseline controls (black) and in 
the presence of 10 M GlyT2 inhibitor (coloured) for each drug. N is shown in white text. Dotted lines 
indicate level of 0 pA. Scale bars are 50 ms and 100 pA. * p <0.05 (paired t test). B) Time plots 
showing glycinergic tonic current amplitude and eIPSC amplitude in response to 10 mM GlyT2 
inhibitor (individual experiments). Coloured bars show period of GlyT2 inhibitor superfusion and the 








Figure 2. NOGly does not increase glycinergic transmission further in the presence of the GlyT2 
inhibitor ORG25543. A) Time plot showing tonic glycinergic current amplitude with baseline 
(black), followed by 5 M ORG25543 (grey), 10 M NOGly (red) and 0.5 M strychnine (black). B) 
Histograms show glycinergic tonic current normalized to baseline and shown as a percentage. Data is 




Figure 3. The effect of GlyT2 inhibitors on the decay time of glycinergic eIPSCs. The effect of 
GlyT2 inhibitors (0.1-100 M) on the decay time of evoked IPSCs in lamina II neurons were measured 
by fitting exponentials to the decay phase of the current traces. Histograms show glycinergic current 
decay times normalized to baseline and shown as a percentage. Examples of glycine-mediated eIPSC 
traces are shown for baseline controls (grey) and in the presence of 10 M GlyT2 inhibitor (coloured) 
for each drug, scaled to baseline amplitude, and with strychnine inhibition of glycine receptors, not 
scaled. N is shown in white text.  Normalized data is presented as mean ± SEM. Scale bars are 25 ms. 




Figure 4. NOGly has no effect on mIPSC amplitude or decay and does not deplete synaptic 
vesicle refilling after prolonged exposure. A) Traces show mIPSC events prior to exposure to 
NOGly (10 M) and post-exposure at 10 and 120 minutes. All mIPSC activity was inhibited by 
strychnine. B) Traces show averaged mIPSC events from the three time points. C) Histograms show 












Figure 5. GlyT2 inhibitors do not increase the amplitude or decay time of NMDA-mediated 
eEPSCs in the dorsal horn. The effect of GlyT2 inhibitors (10 M) on the amplitude and decay time 
of evoked NMDA-mediated eEPSCs in lamina II were examined. A) Histograms show eEPSC 
amplitude shown as a percentage of baseline. B)  Decay constants were measured by fitting 
exponentials to the decay phase of the current traces are shown as a percentage of baseline. C) 
Examples of scaled NMDA-mediated eEPSC traces are shown for baseline controls (grey) and in the 
presence of 10 M GlyT2 inhibitor (coloured) for each drug and with AP5 inhibition of NMDA 
receptors (not scaled). N = 5 for all data sets. Data is presented as mean ± SEM Scale bars are 50 ms. * 

















Figure 6. Nociceptive signalling can be reduced by increasing glycinergic activity in the spinal cord 
dorsal horn through inhibition of the glycine transporter 2 (GlyT2), which increases inhibitory 
signalling through glycine receptors (GlyRs). Since glycine is a co-activator of excitatory NMDA 
receptors (NMDAR), it is important that the increased glycine does not spill-over into the excitatory 
synapses as this may have proalgesic effects.  
 
 
 
 
 
 
